Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Small Cell Lung Carcinoma 52Neoplasms 8Melanoma 8Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Mesothelioma, Malignant 6Mesothelioma 6Colorectal Neoplasms 6Carcinoma 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Respiratory Tract Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Diseases 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Bronchogenic 3Bronchial Neoplasms 3Adenocarcinoma of Lung 3

Interventions

Pemetrexed 2Carboplatin 2durvalumab 1Tretinoin 1Surgical Procedures, Operative 1Paclitaxel 1Observation 1Gemcitabine 1Cisplatin 1Bortezomib 1Azacitidine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × durvalumab × Thoracic × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡